Leerink Partners Reiterates Buy on Xeris Pharmaceuticals Shares, Sees 273% Upside For The Stock

By George MacDonald

In a research report released on 6/18, Leerink Partners analyst Ami Fadia reiterated a Buy rating on Xeris Pharmaceuticals (NASDAQ:XERS)with a price target of $10, which implies an upside of 273% from current levels.

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ami Fadia has a yearly average return of 4.0% and a 49.2% success rate. Fadia has a average return when recommending XERS, and is ranked #2207 out of 6718 analysts.

All the 3 analysts polled by TipRanks rate Xeris Pharmaceuticals stock a Buy. With a return potential of 397.5%, the stock’s consensus target price stands at $13.33.